CAMBRIDGE, MA – April 7, 2023 – HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company, announced today that its scientific work in exploring approaches to target the TIGIT/CD226 axis has been selected for oral presentation at the AACR 2023 meeting during April 14-19, 2023, in Orlando, FL.
“To date, the industry has struggled to successfully develop therapeutics targeting TIGIT, both as a monotherapy and in combination with anti-PD-1/PD-L1 blockers to effectively stimulate the CD226 axis. We believe the next generation of therapies modulating the CD226 axis will need to target additional immune receptors in the axis,” said Jinping Gan, VP Global Head of Research at HiFiBiO Therapeutics. “Through our single cell driven DIS® platform, we have made great progress developing multi-specific approaches for CD226 axis immune modulation in addition to understanding the single cell biology in the tumor microenvironment for indication selection and predictive biomarkers.”
“Beyond our three immune-oncology clinical programs targeting TNFR2, OX40, and BTLA, we continue to explore how the HiFiBiO DIS® approach can transform the drug discovery and development paradigm by integrating deep understanding of immune modulation with a world-leading single cell platform and machine learning-enabled data analysis,” said Francisco Adrian, Chief Scientific Officer of HiFiBiO Therapeutics.
Details on the oral presentation are as follows:
Title: Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer and immunotherapy
Presenter: Jinping Gan, Ph.D., Vice President, Global Head of Research
Session Title: Immune Checkpoints at Tumor Beds
Session Date and Time: Monday, April 17, 2023; 2:30 pm – 4:30 pm
Venue: Valencia D – Convention Center
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage multinational biotherapeutics company advancing a robust pipeline targeting both innate and adaptive immunity to treat cancer and autoimmune disease. Our proprietary and versatile DIS® single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com
HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.